Télécharger le supplément (250 p.) - KCE

More documents

Recommendations

Info

48 Médecine à l’acte/médecine au forfait – ANNEXES KCE Reports 85 S HYPOTHYROÏDIE Tableau 12: Indicateurs retenus Indicator Cf Mesurable a priori 1. The percentage of patients with hypothyroidism with thyroid function test in the previous 15 months DEPISTAGE DU CANCER DU COL Measure to ask Comment 36 oui Within patients under thyroidic hormonotherapy, - number of patients who received a thyroid function test in the previous 15 months Tableau 13: Indicateurs retenus Indicator Cf Mesurable a priori 1. Women should be offered routine screening no less frequently than 5 yearly (unless never sexually active with men or have had a hysterectomy for benign indications) unless refusal is documented 2. Women should be offered routine screening no more frequently than 3 yearly (unless the previous smear was anything other than negative or they are immunodeficient) 3. Women aged > 65 should not be offered screening unless they have had 2 abnormal smears in the previous 5 years 4. For women who have been sexually active, and patients of the practice for at least 2 years, at least 1 Pap test is recorded 5. Percentage of women aged 25-64 screened for cervical abnormalities Test de la fonction thyroïdienne : quel ? Measure to ask Comment 2,3 OUI Cervical screening: A déterminer : âge cible 2,3 2,3 6. Cervical screening uptake 8 7. Uptake rate: target population screened for cervical cancer 10 8. Percentage of eligible women who have had a smear in the last 3 ½ years 9. Percentage of eligible patients recieving cervical screening 10. Performance indicator: fair access: to cancer screening services : % of target population screened for cervical cancer 11. Uptake rate (%): cervical cytology screening rate for the target population 12. Uptake of cervical cytology screening : target to achieve : 80% 1 6 11 13 pour dépistage du cancer du col 14 Performance indicator proposed by the NHS in a national performance framework 18 12 => number (%) of women screened by cervical smears => number and date of cervical smears for each woman. => number and date of cervical smears for women aged >65 years
KCE Reports 85 S Médecine à l’acte/médecine au forfait – ANNEXES 49 13. Percentage vrouwen uit doelcohort bevolkingsonderzoek met een cervixuitstrijke (bruto opkomst) 14. Cancer screening female : papanicolaou test, age 21-64 15. Performance indicator: cervical screening uptake rates 16. The percentage of patients aged 25 to 64 years (in Schotland 25-60 years) whose notes record that a cervical smear has been performed in the last 3 to 5 years DEPISTAGE DU CANCER DU SEIN 26 - ils parlent de taux bruts car ont pris toutes les femmes de la cohorte d’âge concernée alors qu’un taux net tiendrait compte des atcd et de la situation actuelle (ex : grossesse, frottis récent) 28 33 36 Tableau 14: Indicateurs retenus Indicator Cf Mesurable a priori 1. Record that women 50 years and older are referred for, or advised to have, a mammogram every 2 years 2. Proportion of women aged between 50 and 64 years screened for breast cancer 3. Attendance for mammography (age 50-64) 4. Breast screening uptake (age 50- 64) 5. % of eligible women who have had a mammogram in the last 2 ½ years 6. Performance indicators: fair access: for cancer screening services: % of target population screened for breast cancer 7. % vrouwen tussen 50 en 69 jaar van wie het dossier een screeningsmammografie vermeldt van minder dan twee jaar oud (EMD) 8. Patients on HRT should be encouraged to take part in a national mammography screening programme 9. Cancer screening female : mammography test, age 52-64 Measure to ask Comment 1 OUI - Breast Cancer Screening => number (%) of women aged 50 – 69 who screened for breast cancer 8 => number (and dates) of mammography done for each women (time between each mammography) 8 8 11 - tranche d’âge cible en Belgique : 50-69 ans. 14 Indicator proposed by the NHS in a national preformance framework 21 2,3 => all these indicators, specifically for women under hormonal therapy 28 Indicateur porposé dans les sets spécifiques concernant l’hormonothérapie de substitution.
Page 1 and 2: Comparaison du coût et de la quali
Page 3 and 4: Comparaison du coût et de la quali
Page 5 and 6: KCE Reports 85 S Médecine à l’a
Page 51: KCE Reports 85 S Médecine à l’a
Page 103 and 104:
KCE Reports 85 S Médecine à l’a
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
KCE Reports 85 S Médecine à l'act
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
This page is left intentionally bla
Page 247 and 248:
KCE reports 1. Efficacité et renta
Page 249:
74. Oxygénothérapie Hyperbare: Ra
show all

Télécharger le supplément (250 p.) - KCE

Create successful ePaper yourself

Delete template?

Save as template?